The Food and Drug Administration approved the Exablate Neuro system as the first focused ultrasound device intended to treat essential tremor in patients who do not respond to conventional medication.
Please provide your email address to receive an email when new articles are posted on . Acoustic signals from microbubbles can measure how well focused ultrasound opens the blood-brain barrier. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Atrium Health Wake Forest Baptist Medical Center is the ...
Columbia University researchers are the first to show that focused ultrasound—a noninvasive technique that uses sound waves to enhance the delivery of drugs into the brain—can be safely used in ...
New technologies are changing the way we live at a pace that borders on the miraculous. In particular, modern medicine stands as one of humanity’s most awe-inspiring achievements. Technologies like ...
Point-of-Care Ultrasound Devices Market OverviewThe point-of-care ultrasound (POCUS) devices market is witnessing steady expansion and is expected to grow at a compound annual growth rate of ...
Neurotechnology company, Grey Matter Neurosciences, announced it secured $14 million in seed financing, which will be used to develop an ultrasound headset for individuals with Alzheimer's disease and ...
When Graeme F. Woodworth, MD, decided to focus his research efforts on glioblastomas, “everybody thought it was a dead end,” the neurosurgeon recalled. It wasn’t an unusual path for him. His first job ...
The study published in the journal Device is the first to identify an acoustic emissions signature as a reliable measurement for determining opening of the blood-brain barrier “Given the expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results